![](https://i.imgur.com/CLvY2jA.png")
On July 18, 2022, local time, the Catholic University of Chile launched the Phase III clinical study of the SINOVAC quadrivalent influenza virus split vaccine to evaluate the safety and immunogenicity of the vaccine in people aged 3 years and above.
Sinovac's quadrivalent influenza vaccine was approved by the State Food and Drug Administration in China in June 2020, and the clinical study in Chile will help the vaccine's global application.
SINOVAC has a comprehensive influenza vaccine product line, including China's first preservative-free trivalent influenza vaccine, China's first pandemic influenza vaccine (H5N1), the world's first H1N1 influenza vaccine and four Influenza virus split vaccine.
http://www.sinovac.com/news/shownews.php?id=1497
Sinovac's quadrivalent influenza vaccine was approved by the State Food and Drug Administration in China in June 2020, and the clinical study in Chile will help the vaccine's global application.
SINOVAC has a comprehensive influenza vaccine product line, including China's first preservative-free trivalent influenza vaccine, China's first pandemic influenza vaccine (H5N1), the world's first H1N1 influenza vaccine and four Influenza virus split vaccine.
http://www.sinovac.com/news/shownews.php?id=1497
